Efficacy and Safety Outcomes with Diroximel Fumarate in Patients with a History of Prior Sphingosine- 1-Phosphate Receptor Modulators or High-Efficacy Therapies as their Most Recent Therapy: Results from the Phase 3 EVOLVE-MS-1 Study

Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2023
This article has no abstract
Epistemonikos ID: bced3c9f732d6ec79d902bd1532068ff2bcf259e
First added on: Apr 30, 2026